Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

1272290

	registered interest
	date	17/12/2020
	answering body	Home Office
	answering dept id	1
	answering dept short name	Home Office
	answering dept sort name	Home Office
	hansard heading	Police
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for the Home Department, how many no further action notices were issued by the police in each month in (a) 2019 and (b) 2020 in (i) the UK and (ii) each region of the UK.
	tabling member constituency	Nottingham North
	tabling member printed	Alex Norris
	uin	131428
	answer	answer is ministerial correction date of answer 11/01/2021 answer text <p>The Home Offices publishes the investigative outcomes of crimes recorded by the police in England and Wales on a quarterly basis and the latest figures can be found here:</p><p><a href="https://www.gov.uk/government/statistics/police-recorded-crime-open-data-tables" target="_blank">https://www.gov.uk/government/statistics/police-recorded-crime-open-data-tables</a></p><p>However, from the information held centrally, it is not possible to separately identify cases in which a person investigated with regard to a specific offence has been issued with a “No Further Action” notice.</p><p>As policing is a devolved matter, information for Scotland and Northern Ireland is the responsibility of the Scottish Government and the Northern Ireland Assembly.</p> answering member constituency North West Hampshire answering member printed Kit Malthouse question first answered 11/01/2021 11:24:32 answering member 4495 label Biography information for Kit Malthouse
	tabling member	4641 label Biography information for Alex Norris

1455980

	registered interest
	date	30/03/2022
	answering body	Ministry of Justice
	answering dept id	54
	answering dept short name	Justice
	answering dept sort name	Justice
	hansard heading	Drugs: Prison Sentences
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Justice, in the context of reported figures on black people being ten times more likely than white people to be sent to prison for first-time drug offences, what steps he is taking to tackle this imbalance.
	tabling member constituency	Reigate
	tabling member printed	Crispin Blunt
	uin	150059
	answer	answer is ministerial correction date of answer 19/04/2022 answer text <p>We recognise that race disparities persist in the Criminal Justice System, and we are committed to identifying and addressing disparities under the axiom of ‘explain or reform’ laid out in the Lammy Review. And though we acknowledge that Black people are overrepresented amongst those sentenced to prison for a first-time drug offence, this falls short of the reported 10-fold figure.</p><p> </p><p>Recent data indicates that the main drivers of this overrepresentation lie upstream of the point of prosecution. The government’s data on <a href="https://www.gov.uk/government/statistics/criminal-justice-system-statistics-quarterly-december-2020" target="_blank">Outcomes by Offence</a> shows that relative to Black individuals being prosecuted for drug possession, a similar proportion go on to be sentenced for the same offence (15% of individuals identified as Black during prosecution and at the point of sentencing). At the point of sentence, in 2020, 3% of Black individuals were sentenced to immediate custody as a proportion of all Black individuals sentenced for drug possession, which was the same rate as for White individuals, also 3%. These figures suggest that upon reaching prosecution, Black individuals receive outcomes at similar rates to White counterparts. This mirrors the findings of the report from the Commission on Race and Ethnic Disparities, and our ambitious response - the <em>Inclusive Britain</em> strategy, which highlighted the importance of a whole system approach.</p><p>Whilst sentencing is a matter for our independent courts, we are committed to tackling the deep-rooted reasons why people from ethnic minorities are overrepresented in the criminal justice system, including the disproportionate criminalisation of ethnic minorities for drug offences. As set out in <em>Inclusive Britain</em> we have committed to exploring a wide range of schemes to divert people away from the CJS for possession, where appropriate, and will share what works best with police services around the country.</p> answering member constituency North West Hampshire answering member printed Kit Malthouse question first answered 19/04/2022 11:16:20 answering member 4495 label Biography information for Kit Malthouse
	tabling member	104 label Biography information for Crispin Blunt

1379571

	registered interest
	date	17/11/2021
	answering body	Home Office
	answering dept id	1
	answering dept short name	Home Office
	answering dept sort name	Home Office
	hansard heading	Drugs: Misuse
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for the Home Department, pursuant to the Answer of 15 November 2021 on Drugs: Misuse, if she will provide details of the (a) key partners and (b) external experts in the drugs field that have been consulted.
	tabling member constituency	Reigate
	tabling member printed	Crispin Blunt
	uin	76545
	answer	answer is ministerial correction date of answer 22/11/2021 answer text <p>The new Drug Strategy will respond in full to Dame Carol Black’s review and set out our long-term ambition to combat drugs. Parts one and two of Dame Carol Black’s review include comprehensive lists of the experts and wider partners in the drugs field who she engaged with to gather evidence and seek advice.</p><p>We have continued to engage external experts to inform the development of the new Drug Strategy, including Dame Carol Black in her role as independent advisor, Dr Ed Day our National Recovery Champion, and the Advisory Council on the Misuse of Drugs. We also continue to engage wider partners in the drugs field, including the National Police Chiefs Council and substance misuse treatment providers and commissioners.</p><p>We will undertake further engagement with experts and partners in the field to support the implementation of the Strategy and to inform annual reports to Parliament.</p> answering member constituency North West Hampshire answering member printed Kit Malthouse question first answered 22/11/2021 17:24:05 answering member 4495 label Biography information for Kit Malthouse
	tabling member	104 label Biography information for Crispin Blunt

1366349

	registered interest
	date	05/11/2021
	answering body	Home Office
	answering dept id	1
	answering dept short name	Home Office
	answering dept sort name	Home Office
	hansard heading	Drugs: Misuse
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for the Home Department, pursuant to the Answer of 21 October 2021 to Question 58293 on Drugs: Misuse, whether a formal consultation process in line with guidelines has been used in developing the drug strategy, as was the case in the 2010 and other previous drug strategies; how existing external experts were chosen; and to what extent the Advisory Council on the Misuse of Drugs has (a) been involved in the new strategy's development or (b) provided feedback on the draft.
	tabling member constituency	Reigate
	tabling member printed	Crispin Blunt
	uin	70217
	answer	answer is ministerial correction date of answer 15/11/2021 answer text <p>Like the 2017 Drug Strategy, the forthcoming Drug Strategy has been informed by extensive consultation with key partners in the drugs field. This includes through Dame Carol Black’s review of drugs, which involved significant consultation with external partners to gather information.</p><p>The calls for evidence for parts 1 and 2 of the review received responses from a wide range of stakeholders, including members of the public, academics, people working in the substance misuse sector and enforcement partners. Dame Carol also led an extensive programme of consultation events to develop her recommendations on drug treatment for part 2 of her review.</p><p>Our Strategy is responding to Dame Carol Black’s review in full. We have built on the research undertaken as part of the review, and have continued to consult external experts in order to shape the approach and interventions set out in the strategy. This includes Dame Carol Black in her role as independent advisor and Dr Ed Day our national Recovery Champion. The Advisory Council on the Misuse of Drugs’ Full Council has also been briefed on our strategic approach and members of the Council have provided feedback.</p> answering member constituency North West Hampshire answering member printed Kit Malthouse question first answered 15/11/2021 12:54:37 answering member 4495 label Biography information for Kit Malthouse
	tabling member	104 label Biography information for Crispin Blunt

1360592

	registered interest
	date	18/10/2021
	answering body	Home Office
	answering dept id	1
	answering dept short name	Home Office
	answering dept sort name	Home Office
	hansard heading	Drugs: Misuse
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for the Home Department, what plans her Department has for consultation in advance of its forthcoming long term drug strategy.
	tabling member constituency	Reigate
	tabling member printed	Crispin Blunt
	uin	58293
	answer	answer is ministerial correction date of answer 21/10/2021 answer text <p>The Government published its initial response to Dame Carol Black’s independent review of drugs on 27 July, and the upcoming drug strategy will set out our more detailed response to the review’s recommendations. It will present our whole-of-government approach to combating drug misuse by supporting people through treatment and recovery and driving down drug supply and demand.</p><p>We are continuing to engage with external experts across a wide range of sectors in order to shape the approach and interventions set out in the strategy, building on the research undertaken as part of the independent review. Dame Carol is also working with the Government on the development and delivery of the strategy in her new role as an independent advisor.</p> answering member constituency North West Hampshire answering member printed Kit Malthouse question first answered 21/10/2021 16:39:53 answering member 4495 label Biography information for Kit Malthouse
	tabling member	104 label Biography information for Crispin Blunt

1359562

	registered interest
	date	15/10/2021
	answering body	Home Office
	answering dept id	1
	answering dept short name	Home Office
	answering dept sort name	Home Office
	hansard heading	Psilocybin
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for the Home Department, with reference to the oral contribution of the Minister for Crime and Policing of 17 June 2021, Official Report, Column 531, on the Misuse of Drugs Act, what criteria her Department has applied or plans to apply when making an assessment as to whether psilocybin has a proven clinical and medical use for the purposes of determining whether to adapt the relevant legislation.
	tabling member constituency	Reigate
	tabling member printed	Crispin Blunt
	uin	56632
	answer	answer is ministerial correction date of answer 20/10/2021 answer text <p>There is an established process for the development of medicines, which enables medicines (including those containing Schedule 1 drugs such as psilocybin) to be developed, evaluated in clinical trials and licensed based on an assessment of their safety, quality and efficacy.</p><p>The Government recognises that a number of studies into the potential use of psilocybin as part of the treatment for mental health conditions have been or are being conducted in the UK. However, medicines based on psilocybin have not yet been licensed by the Medicines and Healthcare Products Regulatory Authority (MHRA) which would address safety, quality and efficacy concerns. If a psilocybin-based medicine is made available following an assessment of its quality, safety and efficacy by the MHRA, the Home Office will seek and then consider advice provided by the Advisory Council on the Misuse of Drugs (ACMD) on its scheduling under the Misuse of Drugs Regulations 2001 as soon as possible. Such advice is a statutory requirement and will be considered before any decision is taken on scheduling under the 2001 Regulations.</p> answering member constituency North West Hampshire answering member printed Kit Malthouse question first answered 20/10/2021 16:16:12 answering member 4495 label Biography information for Kit Malthouse
	tabling member	104 label Biography information for Crispin Blunt

1357938

	registered interest
	date	23/09/2021
	answering body	Home Office
	answering dept id	1
	answering dept short name	Home Office
	answering dept sort name	Home Office
	hansard heading	Psilocybin: Health Hazards
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for the Home Department, pursuant to the Answer of 7 June 2021 to Question 7725, on Psilocybin: Health Hazards, for what reason her Department has not commissioned a review into the scheduling status of psilocybin in the context of no recent analysis of the evidence for that drug's harm having been commissioned or published by the Government to support the compound being a Class A and a Schedule 1 drug and recent evidence of that drug's clinical and experimental potential.
	tabling member constituency	Reigate
	tabling member printed	Crispin Blunt
	uin	53823
	answer	answer is ministerial correction date of answer 18/10/2021 answer text <p>There is an established process for the development of medicines, which enables medicines (including those containing Schedule 1 drugs such as psilocybin) to be developed, evaluated in clinical trials and licensed based on an assessment of their safety, quality and efficacy.</p><p> </p><p>The Government recognises that a number of studies into the potential use of psilocybin as part of the treatment for mental health conditions have been or are being conducted in the UK. However, medicines based on psilocybin have not yet been licensed by the Medicines and Healthcare Products Regulatory Authority (MHRA) which would address safety, quality and efficacy concerns. Ministers could seek advice from the ACMD about the rescheduling of psilocybin-based products on the basis of evidence of the therapeutic use of unlicensed medicines, but we would ordinarily do this only in consultation with the Department for Health and Social Care and the MHRA.</p><p> </p><p>The MHRA continues to support the safe and scientifically sound conduct of trials in this area and also to provide regulatory and scientific advice to companies at all stages of developing medicines. Should a company apply for a marketing authorisation (a product licence), it will ultimately be a decision for the MHRA whether to license a psilocybin-based medicine as a therapy.</p><p> </p><p>If a psilocybin-based medicine is made available following an assessment of its quality, safety and efficacy by the MHRA, the Home Office will seek and then consider advice provided by the Advisory Council on the Misuse of Drugs (ACMD) on its scheduling under the Misuse of Drugs Regulations 2001 as soon as possible. Such advice is a statutory requirement and will be considered before any decision is taken on scheduling under the 2001 Regulations.</p> answering member constituency North West Hampshire answering member printed Kit Malthouse question first answered 18/10/2021 13:55:12 answering member 4495 label Biography information for Kit Malthouse
	tabling member	104 label Biography information for Crispin Blunt

1343343

	registered interest
	date	02/07/2021
	answering body	Home Office
	answering dept id	1
	answering dept short name	Home Office
	answering dept sort name	Home Office
	hansard heading	Cannabis: Medical Treatments
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for the Home Department, what the evidential basis is for cannabis-based products for medical use to be placed alongside fentanyl and diamorphine in Schedule 2 of the Misuse of Drugs Regulations 2001; and if she will make an assessment of the potential merits of placing such products in lower schedule such as Schedule 4.1 alongside Sativex.
	tabling member constituency	Reigate
	tabling member printed	Crispin Blunt
	uin	26081
	answer	answer is ministerial correction date of answer 07/07/2021 answer text <p>In February 2019, the then Home Secretary commissioned the ACMD to conduct a longer-term review of Cannabis-Based Products for Medicinal use (CBPM). The ACMD published their report on 27 November 2020 on gov.uk. In it they recommended:</p><p><em>“that the scheduling of CBPMs under Schedule 2 of the MDR remains appropriate and that no further legislative amendments to the MDR regarding CBPMs are required at this point in time.”</em></p><p>Unlike Sativex, most CBPM do not have a marketing authorisation from the Medicines and Healthcare products Regulatory Agency (MHRA). As such, in the absence of the reassurance that a CBPM has gone through the safety, quality and efficacy process established by the MHRA, it is right that it is in Schedule 2 of the Misuse of Drugs Regulations 2001. However, should a cannabis-based medicine receive a marketing authorisation from the MHRA, the Government will commission the Advisory Council on the Misuse of Drugs (ACMD) to reconsider the scheduling of the product under the Misuse of Drugs Regulations 2001. This was the case for Sativex following its marketing authorisation.</p> answering member constituency North West Hampshire answering member printed Kit Malthouse question first answered 07/07/2021 15:37:53 answering member 4495 label Biography information for Kit Malthouse
	tabling member	104 label Biography information for Crispin Blunt

1343342

	registered interest
	date	02/07/2021
	answering body	Home Office
	answering dept id	1
	answering dept short name	Home Office
	answering dept sort name	Home Office
	hansard heading	Drugs: Smuggling
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for the Home Department, pursuant to the Answer of 26 May 2021 to Question 5143, what evidence demonstrates that the arrests made have included high-level actors in the trafficking of controlled drugs; and how many of those arrested or charged in relation to Operation VENETIC have been convicted.
	tabling member constituency	Reigate
	tabling member printed	Crispin Blunt
	uin	26080
	answer	answer is ministerial correction date of answer 07/07/2021 answer text <p>The NCA reports that data derived from Operation VENETIC has, to date, led to over 2,300 people being arrested, over 1000 charged and 162 individuals convicted of a range of serious offences. These include well publicised cases of individuals involved in drug trafficking, like Thomas Maher, described by the judge at his trial as “an extremely important cog in the wheel of a sophisticated network”. A large number of cases linked to Operation VENETIC are progressing through the criminal justice system and it would be inappropriate to comment further on these at this time. The NCA regularly publishes the outcomes of investigations via press notices on its website.</p><p> </p> answering member constituency North West Hampshire answering member printed Kit Malthouse question first answered 07/07/2021 15:23:38 answering member 4495 label Biography information for Kit Malthouse
	tabling member	104 label Biography information for Crispin Blunt

1343151

	registered interest
	date	01/07/2021
	answering body	Home Office
	answering dept id	1
	answering dept short name	Home Office
	answering dept sort name	Home Office
	hansard heading	Drugs: Misuse
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for the Home Department, pursuant to the Answer of 11 June 2020 to Question 11461 on Drugs: Misuse, for what reason the crimes referred to in that Answer that would be associated with a medically supervised drug consumption clinic do not apply to (a) needle and syringe programmes for injecting drug users and (b) other programmes and services that engage those users.
	tabling member constituency	Reigate
	tabling member printed	Crispin Blunt
	uin	25705
	answer	answer is ministerial correction date of answer 06/07/2021 answer text <p>Needle and syringe programmes and other programmes and services that engage drug users do not involve the organiser condoning and facilitating consumption of controlled drugs on the premises, nor do they create spaces where police enforcement of the law in relation to drug possession and supply is compromised.</p><p>Drug Consumption Rooms would not be lawful in the UK due to the offences which would be committed in the course of running such a facility.</p> answering member constituency North West Hampshire answering member printed Kit Malthouse grouped question UIN 25704 question first answered 06/07/2021 08:10:29 answering member 4495 label Biography information for Kit Malthouse
	tabling member	104 label Biography information for Crispin Blunt